Skip to main content

SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

EVOLVE Short DAPT

3-month DAPT in High Bleeding Risk (HBR) patients undergoing PCI with the SYNERGY BP-DES

Fast Facts Sign Up
icon_document.png

Indications, Safety, and Warnings

 icon-send-questions.png

Frequently Asked Questions

 icon-contact-email

Request a Sales Rep
 
 

Studies the safety of discontinuing DAPT at 3-months in this HBR patient population using the SYNERGY BP-DES.*

Now Indicated for Use in High Bleeding Risk Patients
 

Trial Design

  • Prospective, multicenter, single-arm trial
  • 2,009 patients with significant bleeding risks at 110 global sites
  • Primary endpoint data collected from 1,487 patients eligible to discontinue DAPT at 3-months.
 

Clinical Outcomes at 12-months Post-DAPT Discontinuation

Co-Primary Endpoint: SYNERGY BP Stent-Related ARC Definite/Probable ST Between 3-15M

 
0.2% ST WITH 3-MONTH DAPT
SYNERGY BP-Stent demonstrated low stent thrombosis in the 12 months following 3-month DAPT
0.2% ST WITH 3-MONTH DAPT
 

Co-Primary Endpoint: Adjusted Death/MI Between 3-15M with 3M DAPT Compared to Historical Control

 
03-MONTH DAPT NON-INFERIOR TO 12-MONTH DAPT
Studies the safety of SYNERGY BP-DES with 3-month DAPT in this high bleeding risk population
3-MONTH DAPT NON-INFERIOR TO 12-MONTH DAPT
 
 
Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Real-World Studies

Real-World Studies

Low event rates in real-world studies

Button
Early Healing

Early Healing

Advanced design for optimal healing

Button
 
Top